Engene Holdings WT (ENGNW)

$1.97 -0.13 (-6.19%)
Market Cap N/A
Revenue (ttm) 0.00
Net Income (ttm) -99.92M
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin N/A
Debt to Equity Ratio N/A
Volume 815
Avg Vol 5,100
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K 57%
Beta N/A
Analysts Strong Sell
Price Target N/A

Company Profile

enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2. The company was formerly known as enGene Holdings Inc. and changed its name to enGene Therapeutics Inc...

Phone: 514 332 4888
Address:
4868 Rue Levy, Suite 220, Montreal, Canada
Latest News on ENGNW
Leerink downgraded enGene to Market Perform following LEGEND update

2026-05-08T18:32:38.000Z - 5 days ago

Leerink downgraded enGene to Market Perform following LEGEND update

enGene downgraded to Perform from Outperform at Oppenheimer

2026-05-08T16:22:56.000Z - 5 days ago

enGene downgraded to Perform from Outperform at Oppenheimer

enGene downgraded to Market Perform from Outperform at Leerink

2026-05-08T12:11:57.000Z - 5 days ago

enGene downgraded to Market Perform from Outperform at Leerink

enGene downgraded to Outperform from Strong Buy at Raymond James

2026-05-08T09:16:27.000Z - 5 days ago

enGene downgraded to Outperform from Strong Buy at Raymond James

enGene downgraded to Neutral from Buy at Guggenheim

2026-05-08T09:15:51.000Z - 5 days ago

enGene downgraded to Neutral from Buy at Guggenheim

enGene downgraded to Neutral from Overweight at Piper Sandler

2026-05-08T09:10:12.000Z - 5 days ago

enGene downgraded to Neutral from Overweight at Piper Sandler

enGene downgraded to Market Perform from Outperform at Citizens

2026-05-08T09:00:14.000Z - 5 days ago

enGene downgraded to Market Perform from Outperform at Citizens

enGene downgraded to Equal Weight from Overweight at Wells Fargo

2026-05-08T00:55:12.000Z - 5 days ago

enGene downgraded to Equal Weight from Overweight at Wells Fargo

enGene downgraded to Equal Weight from Overweight at Morgan Stanley

2026-05-07T22:42:47.000Z - 6 days ago

enGene downgraded to Equal Weight from Overweight at Morgan Stanley

enGene downgraded to Neutral from Buy at Guggenheim

2026-05-07T21:51:44.000Z - 6 days ago

enGene downgraded to Neutral from Buy at Guggenheim

enGene Therapeutics Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

May 7, 2026, 3:35 PM EDT - 6 days ago

enGene Therapeutics Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

enGene announces updated interim results from LEGEND cohort

2026-05-07T14:15:38.000Z - 6 days ago

enGene announces updated interim results from LEGEND cohort

enGene Therapeutics Transcript: Study result

May 7, 2026, 8:00 AM EDT - 6 days ago

enGene Therapeutics Transcript: Study result

enGene Announces Updated Interim Results From LEGEND Pivotal Cohort

May 7, 2026, 7:00 AM EDT - 6 days ago

enGene Announces Updated Interim Results From LEGEND Pivotal Cohort

enGene initiated with a Buy at WBB Securities

2026-04-13T11:21:48.000Z - 4 weeks ago

enGene initiated with a Buy at WBB Securities

enGene announces name change to enGene Therapeutics

2026-04-07T12:22:18.000Z - 5 weeks ago

enGene announces name change to enGene Therapeutics

enGene Announces Name Change to enGene Therapeutics Inc.

Apr 7, 2026, 8:00 AM EDT - 5 weeks ago

enGene Announces Name Change to enGene Therapeutics Inc.

Three new option listings and three option delistings on April 6th

2026-04-06T12:30:37.000Z - 5 weeks ago

Three new option listings and three option delistings on April 6th

TBHC

enGene price target lowered to $9 from $10 at UBS

2026-03-22T14:50:06.000Z - 7 weeks ago

enGene price target lowered to $9 from $10 at UBS

enGene Therapeutics Transcript: The Citizens Life Sciences Conference 2026

Mar 11, 2026, 1:40 PM EDT - 2 months ago

enGene Therapeutics Transcript: The Citizens Life Sciences Conference 2026

enGene price target lowered to $30 from $33 at Oppenheimer

2026-03-11T11:56:47.000Z - 2 months ago

enGene price target lowered to $30 from $33 at Oppenheimer

enGene Therapeutics Transcript: Barclays 28th Annual Global Healthcare Conference

Mar 10, 2026, 9:00 AM EDT - 2 months ago

enGene Therapeutics Transcript: Barclays 28th Annual Global Healthcare Conference

enGene price target lowered to $27 from $30 at Guggenheim

2026-03-10T10:56:28.000Z - 2 months ago

enGene price target lowered to $27 from $30 at Guggenheim

enGene Therapeutics Transcript: Leerink Global Healthcare Conference 2026

Mar 9, 2026, 8:00 AM EDT - 2 months ago

enGene Therapeutics Transcript: Leerink Global Healthcare Conference 2026

enGene Reports First Quarter 2026 Financial Results and Provides Business Update

Mar 9, 2026, 7:00 AM EDT - 2 months ago

enGene Reports First Quarter 2026 Financial Results and Provides Business Update

enGene Therapeutics Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 26, 2026, 1:20 PM EST - 2 months ago

enGene Therapeutics Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

enGene to Participate in Upcoming Investor Conferences

Feb 20, 2026, 8:00 AM EST - 2 months ago

enGene to Participate in Upcoming Investor Conferences

enGene files $400M mixed securities shelf

2026-02-19T21:36:08.000Z - 2 months ago

enGene files $400M mixed securities shelf

enGene Therapeutics Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Feb 11, 2026, 2:30 PM EST - 3 months ago

enGene Therapeutics Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

enGene to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

Feb 4, 2026, 8:00 AM EST - 3 months ago

enGene to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

enGene Announces Expanded $125 Million Debt Facility with Hercules Capital, Inc.

Jan 20, 2026, 5:35 PM EST - 4 months ago

enGene Announces Expanded $125 Million Debt Facility with Hercules Capital, Inc.

HTGC

enGene Reports Full Year 2025 Financial Results and Provides Business Update

Dec 22, 2025, 4:03 PM EST - 5 months ago

enGene Reports Full Year 2025 Financial Results and Provides Business Update

enGene Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference

Dec 2, 2025, 12:10 PM EST - 5 months ago

enGene Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference

enGene's Detalimogene Selected for FDA Manufacturing Pilot Program to Support Manufacturing Readiness

Dec 2, 2025, 7:30 AM EST - 5 months ago

enGene's Detalimogene Selected for FDA Manufacturing Pilot Program to Support Manufacturing Readiness

enGene to Present at the Piper Sandler 37th Annual Healthcare Conference

Nov 25, 2025, 7:30 AM EST - 6 months ago

enGene to Present at the Piper Sandler 37th Annual Healthcare Conference

enGene Therapeutics Transcript: Jefferies London Healthcare Conference 2025

Nov 18, 2025, 3:30 AM EST - 6 months ago

enGene Therapeutics Transcript: Jefferies London Healthcare Conference 2025

enGene Announces Pricing of $130 Million Public Offering of Common Shares and Pre-Funded Warrants

Nov 13, 2025, 12:27 AM EST - 6 months ago

enGene Announces Pricing of $130 Million Public Offering of Common Shares and Pre-Funded Warrants

enGene Announces Proposed Public Offering of Common Shares

Nov 12, 2025, 4:01 PM EST - 6 months ago

enGene Announces Proposed Public Offering of Common Shares

enGene Therapeutics Transcript: Stifel 2025 Healthcare Conference

Nov 12, 2025, 2:00 PM EST - 6 months ago

enGene Therapeutics Transcript: Stifel 2025 Healthcare Conference

enGene Therapeutics Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 11, 2025, 12:30 PM EST - 6 months ago

enGene Therapeutics Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

enGene Therapeutics Transcript: Study Update

Nov 11, 2025, 8:00 AM EST - 6 months ago

enGene Therapeutics Transcript: Study Update

Detalimogene Demonstrates Improved Complete Response Rate of 62% at 6 Months

Nov 11, 2025, 7:30 AM EST - 6 months ago

Detalimogene Demonstrates Improved Complete Response Rate of 62% at 6 Months

enGene to Host Conference Call to Provide Update on Pivotal Cohort of LEGEND Trial

Nov 10, 2025, 4:05 PM EST - 6 months ago

enGene to Host Conference Call to Provide Update on Pivotal Cohort of LEGEND Trial

enGene Named a BioSpace 2026 Best Places to Work Winner

Nov 4, 2025, 1:35 PM EST - 6 months ago

enGene Named a BioSpace 2026 Best Places to Work Winner

enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Oct 1, 2025, 4:03 PM EDT - 8 months ago

enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

enGene Appoints Hussein Sweiti, M.D., MSc, as Chief Medical Officer

Sep 30, 2025, 7:30 AM EDT - 8 months ago

enGene Appoints Hussein Sweiti, M.D., MSc, as Chief Medical Officer

enGene Reports Third Quarter 2025 Financial Results and Provides Business Update

Sep 11, 2025, 4:03 PM EDT - 8 months ago

enGene Reports Third Quarter 2025 Financial Results and Provides Business Update

enGene Therapeutics Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 10, 2025, 1:50 PM EDT - 8 months ago

enGene Therapeutics Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

enGene Therapeutics Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Sep 3, 2025, 8:45 AM EDT - 9 months ago

enGene Therapeutics Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

enGene Achieves Target Enrollment Milestone for LEGEND Trial Pivotal Cohort

Sep 3, 2025, 7:30 AM EDT - 9 months ago

enGene Achieves Target Enrollment Milestone for LEGEND Trial Pivotal Cohort

enGene Announces Board and Leadership Appointments to Support Commercial Readiness

Jul 8, 2025, 8:00 AM EDT - 11 months ago

enGene Announces Board and Leadership Appointments to Support Commercial Readiness

FDA Grants RMAT Designation for enGene's Detalimogene, Enabling Potential for Expedited Review in High-Risk, Non-Muscle Invasive Bladder Cancer

Jun 25, 2025, 8:00 AM EDT - 11 months ago

FDA Grants RMAT Designation for enGene's Detalimogene, Enabling Potential for Expedited Review in High-Risk, Non-Muscle Invasive Bladder Cancer

enGene Reports Second Quarter 2025 Financial Results and Provides Business Update

Jun 12, 2025, 8:00 AM EDT - 11 months ago

enGene Reports Second Quarter 2025 Financial Results and Provides Business Update

enGene Therapeutics Transcript: Jefferies Global Healthcare Conference 2025

Jun 4, 2025, 11:05 AM EDT - 1 year ago

enGene Therapeutics Transcript: Jefferies Global Healthcare Conference 2025

enGene Announces the Resignation of its Chief Medical Officer

Jun 4, 2025, 8:30 AM EDT - 1 year ago

enGene Announces the Resignation of its Chief Medical Officer

enGene to Present at the Jefferies Global Healthcare Conference

May 29, 2025, 8:00 AM EDT - 1 year ago

enGene to Present at the Jefferies Global Healthcare Conference

enGene Names Amy Pott as Chief Global Commercialization Officer

May 28, 2025, 7:30 AM EDT - 1 year ago

enGene Names Amy Pott as Chief Global Commercialization Officer

enGene Therapeutics Transcript: The Citizens JMP Life Sciences Conference 2025

May 7, 2025, 11:30 AM EDT - 1 year ago

enGene Therapeutics Transcript: The Citizens JMP Life Sciences Conference 2025

enGene Therapeutics Transcript: Bloom Burton & Co. Healthcare Investor Conference 2025

May 5, 2025, 2:00 PM EDT - 1 year ago

enGene Therapeutics Transcript: Bloom Burton & Co. Healthcare Investor Conference 2025

enGene Therapeutics Transcript: Stifel 2025 Virtual Targeted Oncology Forum

Apr 8, 2025, 4:00 PM EDT - 1 year ago

enGene Therapeutics Transcript: Stifel 2025 Virtual Targeted Oncology Forum

enGene to Present at the Stifel 2025 Virtual Targeted Oncology Forum

Apr 1, 2025, 8:00 AM EDT - 1 year ago

enGene to Present at the Stifel 2025 Virtual Targeted Oncology Forum

enGene Therapeutics Transcript: Leerink’s Global Healthcare Conference 2025

Mar 11, 2025, 1:00 PM EDT - 1 year ago

enGene Therapeutics Transcript: Leerink’s Global Healthcare Conference 2025

enGene Reports First Quarter 2025 Financial Results and Provides Business Update

Mar 10, 2025, 4:05 PM EDT - 1 year ago

enGene Reports First Quarter 2025 Financial Results and Provides Business Update

enGene to Participate in the Leerink Partners Global Healthcare Conference

Mar 4, 2025, 8:00 AM EST - 1 year ago

enGene to Participate in the Leerink Partners Global Healthcare Conference

enGene Therapeutics Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 2025

Feb 11, 2025, 8:40 AM EST - 1 year ago

enGene Therapeutics Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 2025

enGene to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Feb 4, 2025, 8:00 AM EST - 1 year ago

enGene to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

enGene to Present Three Posters at the 2025 ASCO Genitourinary Cancers Symposium (ASCO GU) Highlighting the Ongoing Clinical Development of Detalimogene Voraplasmid for the Treatment of Non-Muscle Invasive Bladder Cancer (NMIBC)

Jan 30, 2025, 8:00 AM EST - 1 year ago

enGene to Present Three Posters at the 2025 ASCO Genitourinary Cancers Symposium (ASCO GU) Highlighting the Ongoing Clinical Development of Detalimogene Voraplasmid for the Treatment of Non-Muscle Invasive Bladder Cancer (NMIBC)

enGene Reports Full Year 2024 Financial Results and Provides a Business Update

Dec 19, 2024, 4:05 PM EST - 1 year ago

enGene Reports Full Year 2024 Financial Results and Provides a Business Update

enGene Therapeutics Transcript: Piper Sandler 36th Annual Healthcare Conference

Dec 3, 2024, 3:00 PM EST - 1 year ago

enGene Therapeutics Transcript: Piper Sandler 36th Annual Healthcare Conference

enGene Therapeutics Transcript: JMP Hematology and Oncology Summit 2024

Dec 2, 2024, 10:00 AM EST - 1 year ago

enGene Therapeutics Transcript: JMP Hematology and Oncology Summit 2024

enGene Therapeutics Transcript: Guggenheim’s Inaugural Healthcare Innovation Conference

Nov 12, 2024, 10:30 AM EST - 1 year ago

enGene Therapeutics Transcript: Guggenheim’s Inaugural Healthcare Innovation Conference

enGene to Participate in Guggenheim's Inaugural Healthcare Innovation Conference

Nov 5, 2024, 8:00 AM EST - 1 year ago

enGene to Participate in Guggenheim's Inaugural Healthcare Innovation Conference

enGene Announces $60 Million Private Placement Financing

Oct 25, 2024, 8:00 AM EDT - 1 year ago

enGene Announces $60 Million Private Placement Financing

enGene Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Oct 22, 2024, 4:05 PM EDT - 1 year ago

enGene Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

enGene Appoints Joan Connolly as Chief Technology Officer and Anthony Cheung, Ph.D., as Chief Scientific Officer

Oct 21, 2024, 8:45 AM EDT - 1 year ago

enGene Appoints Joan Connolly as Chief Technology Officer and Anthony Cheung, Ph.D., as Chief Scientific Officer

Detalimogene Demonstrates 71% Complete Response Rate at Any Time in Preliminary Analysis of LEGEND Pivotal Cohort

Sep 26, 2024, 6:30 AM EDT - 1 year ago

Detalimogene Demonstrates 71% Complete Response Rate at Any Time in Preliminary Analysis of LEGEND Pivotal Cohort

enGene Therapeutics Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Sep 11, 2024, 9:30 AM EDT - 1 year ago

enGene Therapeutics Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

enGene Reports Third Quarter 2024 Financial Results and Provides a Business Update

Sep 10, 2024, 4:33 PM EDT - 1 year ago

enGene Reports Third Quarter 2024 Financial Results and Provides a Business Update

enGene Therapeutics Transcript: 2024 Wells Fargo Healthcare Conference

Sep 6, 2024, 11:00 AM EDT - 1 year ago

enGene Therapeutics Transcript: 2024 Wells Fargo Healthcare Conference

enGene Therapeutics Transcript: Morgan Stanley 22nd Annual Global Healthcare Conference

Sep 5, 2024, 4:50 PM EDT - 1 year ago

enGene Therapeutics Transcript: Morgan Stanley 22nd Annual Global Healthcare Conference

enGene Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Jul 24, 2024, 4:05 PM EDT - 1 year ago

enGene Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

enGene Announces Appointment of Ron Cooper as Chief Executive Officer

Jul 24, 2024, 6:30 AM EDT - 1 year ago

enGene Announces Appointment of Ron Cooper as Chief Executive Officer

enGene Reports Second Quarter 2024 Financial Results and Provides a Business Update

Jun 14, 2024, 7:01 AM EDT - 2 years ago

enGene Reports Second Quarter 2024 Financial Results and Provides a Business Update

enGene Therapeutics Transcript: Jefferies 2024 Global Healthcare Conference

Jun 5, 2024, 12:30 PM EDT - 2 years ago

enGene Therapeutics Transcript: Jefferies 2024 Global Healthcare Conference

enGene Announces the Election of Paul Hastings and Wouter Joustra to its Board of Directors

May 15, 2024, 4:05 PM EDT - 2 years ago

enGene Announces the Election of Paul Hastings and Wouter Joustra to its Board of Directors

enGene to Present Details of its Pivotal Phase 1/2 LEGEND Study of EG-70 in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in situ at the American Urology Association 2024 Annual Meeting

May 2, 2024, 4:05 PM EDT - 2 years ago

enGene to Present Details of its Pivotal Phase 1/2 LEGEND Study of EG-70 in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in situ at the American Urology Association 2024 Annual Meeting

/C O R R E C T I O N -- enGene Inc./

Apr 9, 2024, 8:56 AM EDT - 2 years ago

/C O R R E C T I O N -- enGene Inc./

enGene Announces Hiring of Dr. Raja Ruth as Senior Vice President, Urologic Oncology and Clinical Development

Apr 9, 2024, 8:00 AM EDT - 2 years ago

enGene Announces Hiring of Dr. Raja Ruth as Senior Vice President, Urologic Oncology and Clinical Development

enGene Reports First Quarter 2024 Financial Results and Recent Corporate Progress

Mar 11, 2024, 5:16 PM EDT - 2 years ago

enGene Reports First Quarter 2024 Financial Results and Recent Corporate Progress

enGene To Present at the Leerink Partners Global Biopharma Conference

Mar 5, 2024, 7:00 AM EST - 2 years ago

enGene To Present at the Leerink Partners Global Biopharma Conference

enGene Announces Oversubscribed $200 Million Private Placement Financing

Feb 14, 2024, 6:50 AM EST - 2 years ago

enGene Announces Oversubscribed $200 Million Private Placement Financing

enGene Announces Leadership Succession Plan

Feb 14, 2024, 6:45 AM EST - 2 years ago

enGene Announces Leadership Succession Plan

enGene Appoints Lee Giguere as Chief Legal Officer and Corporate Secretary

Jan 30, 2024, 7:00 AM EST - 2 years ago

enGene Appoints Lee Giguere as Chief Legal Officer and Corporate Secretary

enGene Reports Full Year 2023 Financial Results and Recent Operational Progress

Jan 29, 2024, 7:00 AM EST - 2 years ago

enGene Reports Full Year 2023 Financial Results and Recent Operational Progress